SEC Stock Data Quick Answer Yubo International Biotech Ltd reported Stockholders Equity of -$1.95 million for fiscal year 2025. Yubo International Biotech Ltd Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$1.95M +42.9% 2024 -$3.42M -85.7% 2023 -$1.84M -226.1% 2022 -$565.4K -330.9% 2021 -$131.2K -111.2% 2020 $1.17M +164.9% 2020 -$1.80M -467.9% 2019 $488.7K +129.4% … Read more
Quick Answer Yubo International Biotech Ltd reported Cash and Equivalents of $27.5 thousand for fiscal year 2021. Yubo International Biotech Ltd Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2021 $27.5K -98.0% 2020 $1.38M +138152.4% 2020 $1.0K -20.8% 2019 $1.3K -68.5% 2019 $4.0K +100.0% 2018 $2.0K +100.0% 2017 $1.0K -90.9% … Read more
Quick Answer Yubo International Biotech Ltd reported Total Assets of $847.1 thousand for fiscal year 2025. Yubo International Biotech Ltd Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $847.1K -44.8% 2024 $1.53M -7.9% 2023 $1.67M -29.0% 2022 $2.35M -48.8% 2021 $4.59M +87.6% 2020 $2.44M +244387.6% 2020 $1.0K -75.0% 2019 $4.0K — … Read more
Quick Answer Yubo International Biotech Ltd reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025. Yubo International Biotech Ltd Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.01 +50.0% 2024 -$0.02 +80.0% 2023 -$0.10 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 $0.00 … Read more
Quick Answer Yubo International Biotech Ltd reported Net Income of -$1.08 million for fiscal year 2025. Yubo International Biotech Ltd Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$1.08M +39.2% 2024 -$1.78M -48.6% 2023 -$1.20M +0.8% 2022 -$1.20M +21.9% 2021 -$1.54M -116.7% 2020 -$711.8K -431.2% 2020 -$134.0K +9.5% 2019 -$148.0K -2.8% … Read more
Quick Answer Yubo International Biotech Ltd reported Total Revenue of $12.4 thousand for fiscal year 2025. Yubo International Biotech Ltd Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $12.4K +256.0% 2024 $3.5K -99.4% 2023 $604.7K +479.8% 2022 $104.3K -91.6% 2021 $1.24M — 2020 $0.00 — 2019 $0.00 — 2018 $0.00 — … Read more
Quick Answer Yubo International Biotech Ltd reported Total Revenue of $12.4 thousand for fiscal year 2025. Yubo International Biotech Ltd — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $12.4K+256.0% $3.5K-99.4% $604.7K+479.8% $104.3K-91.6% $1.24M $0.00 Net Income -$1.08M+39.2% -$1.78M-48.6% -$1.20M+0.8% -$1.20M+21.9% -$1.54M-1051.1% -$134.0K+9.5% Diluted EPS -$0.01+50.0% -$0.02+80.0% -$0.10 — — … Read more
Quick Answer Yalla Group Ltd reported Shares Outstanding of 73.39 million shares for fiscal year 2019. Yalla Group Ltd Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2019 73.39M — The most recent figure is from Yalla Group Ltd’s fiscal year 2021 report (Form 20-F), filed with the SEC on April 25, … Read more
Quick Answer Yalla Group Ltd reported Operating Income of $121.40 million for fiscal year 2024. Yalla Group Ltd Operating Income — Annual History Fiscal Year Operating Income YoY Change 2024 $121.40M +26.0% 2023 $96.35M +22.4% 2022 $78.70M -5.2% 2021 $83.03M +2108.9% 2020 $3.76M -87.0% 2019 $28.94M +42.2% 2018 $20.35M — Yalla Group Ltd showed an … Read more
Quick Answer Yalla Group Ltd reported R&D Expense of $29.03 million for fiscal year 2024. Yalla Group Ltd R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2024 $29.03M +12.5% 2023 $25.80M +5.0% 2022 $24.58M +72.0% 2021 $14.29M +173.6% 2020 $5.22M +226.8% 2019 $1.60M — Yalla Group Ltd showed an increase of +12.5% … Read more